These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37182087)

  • 1. Sodium-Glucose Cotransporter 2 Inhibitors: A Scoping Review of the Positive Implications on Cardiovascular and Renal Health and Dynamics for Clinical Practice.
    Erdem S; Titus A; Patel D; Patel NN; Sattar Y; Glazier J; Alraies MC
    Cureus; 2023 Apr; 15(4):e37310. PubMed ID: 37182087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.
    Gonzalez J; Bates BA; Setoguchi S; Gerhard T; Dave CV
    Cardiovasc Diabetol; 2023 Mar; 22(1):54. PubMed ID: 36899387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use Sodium Glucose Cotransporter 2 inhibitors is now.
    Johansen ME; Argyropoulos C
    Clin Cardiol; 2020 Dec; 43(12):1376-1387. PubMed ID: 33165977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure.
    Ji PJ; Zhang ZY; Yan Q; Cao HL; Zhao YJ; Yang B; Li J
    ESC Heart Fail; 2023 Apr; 10(2):1314-1325. PubMed ID: 36722326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis.
    Wang Y; Gao T; Meng C; Li S; Bi L; Geng Y; Zhang P
    Eur J Med Res; 2022 Dec; 27(1):314. PubMed ID: 36581880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis.
    Banerjee M; Pal R; Nair K; Mukhopadhyay S
    Indian Heart J; 2023; 75(2):122-127. PubMed ID: 36914068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
    Xiang B; Zhang R; Wu X; Zhou X
    JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose cotransporter 2 inhibitor-induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction.
    Cavka L; Bencak Ferko U; Pitz N; Trpkovski Z; Lainscak M
    ESC Heart Fail; 2021 Aug; 8(4):2631-2636. PubMed ID: 34102028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms.
    Savarese G; Butler J; Lund LH; Bhatt DL; Anker SD
    Cardiovasc Res; 2022 Jul; 118(10):2231-2252. PubMed ID: 34390570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity in cardiorenal protection by Sodium glucose cotransporter 2 inhibitors in heart failure across the ejection fraction strata: Systematic review and meta-analysis.
    Taheri S
    World J Nephrol; 2023 Dec; 12(5):182-200. PubMed ID: 38230296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardio-renal-metabolic syndrome: clinical features and dapagliflozin eligibility in a real-world heart failure cohort.
    Beles M; Masuy I; Verstreken S; Bartunek J; Dierckx R; Heggermont W; Oeste C; De Boeck M; Fovel I; Maris M; Vermeulen Z; Vanderheyden M
    ESC Heart Fail; 2023 Aug; 10(4):2269-2280. PubMed ID: 37095712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles for SGLT2 Inhibitors in Cardiorenal Disease.
    Green JB; McCullough PA
    Cardiorenal Med; 2022; 12(3):81-93. PubMed ID: 35835083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons from a pre-specified meta-analysis of sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure: Time for new clinical recommendations.
    Kotit S
    Glob Cardiol Sci Pract; 2023 May; 2023(2):e202314. PubMed ID: 37351098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Review of Sodium-Glucose Cotransporter 2 Inhibitor's Clinical Efficacy in Heart Failure With Preserved Ejection Fraction.
    Epperson J; Athar ZM; Arshad M; Chen E
    Cureus; 2024 Apr; 16(4):e57380. PubMed ID: 38694659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.
    Cheema HA; Shafiee A; Athar MMT; Rafiei MA; Mehmannavaz A; Jafarabady K; Shahid A; Ahmad A; Ijaz SH; Dani SS; Minhas AMK; Nashwan AJ; Fudim M; Fonarow GC
    Front Cardiovasc Med; 2023; 10():1273781. PubMed ID: 37900570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial Effects of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure With Preserved Ejection Fraction and Diabetes.
    Enzan N; Matsushima S; Kaku H; Tohyama T; Nagata T; Ide T; Tsutsui H
    JACC Asia; 2023 Feb; 3(1):93-104. PubMed ID: 36873765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-Glucose Cotransporter-2 Inhibitor Use is Associated with a Reduced Risk of Heart Failure Hospitalization in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus: A Real-World Study on a Diverse Urban Population.
    Li W; Katamreddy A; Kataria R; Myerson ML; Taub CC
    Drugs Real World Outcomes; 2022 Mar; 9(1):53-62. PubMed ID: 34478119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction.
    De Lorenzi AB; Kaplinsky E; Zambrano MR; Chaume LT; Rosas JM
    Drugs Context; 2023; 12():. PubMed ID: 36660013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promise of sodium-glucose co-transporter-2 inhibitors in heart failure with mildly reduced ejection fraction.
    Shen X; Shen X
    ESC Heart Fail; 2022 Aug; 9(4):2239-2248. PubMed ID: 35642772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.